| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹764.2 0% | 2,600 | ₹0.95 0% | 2500% |
| 5000% | ₹587 0% | 2,800 | ₹0.1 -91.66% | 4,2500% |
| - | - | 2,900 | ₹0.7 0% | 14,500-1.69% |
| 5000% | ₹425.95 0% | 2,950 | ₹3.5 0% | 47,2500% |
| 1,2500% | ₹366.1 0% | 3,000 | ₹1 -33.33% | 40,750-1.21% |
| 5000% | ₹366.8 0% | 3,050 | ₹1.25 -3.84% | 14,500-3.33% |
| 3,2500% | ₹349 0% | 3,100 | ₹1.8 0% | 52,5000% |
| 1,2500% | ₹227 0% | 3,150 | ₹1.15 -17.85% | 12,750-7.27% |
| 18,250-3.94% | ₹330 -1.09% | 3,200 | ₹3 25% | 40,000-1.23% |
| 20,0000% | ₹130.45 0% | 3,250 | ₹3.6 -8.86% | 24,2500% |
| 43,2500% | ₹217.45 0.81% | 3,300 | ₹5.3 -25.87% | 74,250-1% |
| 1,40,000-0.17% | ₹183.35 9.13% | 3,350 | ₹7.7 -34.46% | 40,5007.28% |
| 2,04,750-0.36% | ₹138.9 8% | 3,400 | ₹13.7 -32% | 1,40,2508.93% |
| 76,2501.66% | ₹98.3 6.84% | 3,450 | ₹24.15 -27.25% | 25,25048.52% |
| 1,36,7505.19% | ₹69 11.02% | 3,500 | ₹42.85 -18.69% | 74,75019.12% |
| 1,02,7505.11% | ₹42.15 5.37% | 3,550 | ₹65 -18.9% | 17,50025% |
| 2,23,2500.79% | ₹26.85 10.72% | 3,600 | ₹95 -16.29% | 5,25010.52% |
| 50,7508.55% | ₹16.4 13.1% | 3,650 | ₹319.45 0% | 2500% |
| 1,03,5006.15% | ₹9.3 3.91% | 3,700 | ₹186.2 -45.21% | 1,250-16.66% |
| 14,7503.50% | ₹4.5 -23.72% | 3,750 | ₹384.05 0% | 1,2500% |
| 1,17,000-12.84% | ₹4.8 12.94% | 3,800 | ₹430.5 0% | 2500% |
| 21,000-20.75% | ₹2 -13.04% | 3,900 | - | - |
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
